Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study
ConclusionsTrifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma.
Source: Esophagus - Category: Gastroenterology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Gastroenterology | Japan Health | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology